LYFE Capital leads Jianjia Robot Series C
Jianjia Robot completed a Series C round to advance clinical trials and registration of its orthopaedic surgical-robot portfolio.
Evidence notes
- LYFE Capital led the round, with SoftBank China Capital participating and Hillhouse Ventures and Fosun Pharma returning.
- Jianjia allocated the proceeds to knee-replacement robot trials and development and registration of additional surgical robots.
- Its hip-replacement robot had completed clinical enrolment and follow-up by the round announcement.
Company context
Jianjia Medical is a Chinese orthopaedic surgical-robotics company developing Arthrobot and multimodal navigation systems for joint, spine and trauma procedures.